Disease Landscape and Forecast Insights

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the growing…

Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2029. The treatment of metastatic colorectal cancer is…

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…

Hepatitis B virus (HBV) infection is a major public health burden in China, and chronically infected HBV patients are at a high risk of developing hepatic cirrhosis and hepatocellular carcinoma…

Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved to treat this indication—Roche’s Herceptin as…

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therapies…

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as biguanides, insulin secretagogues (…

MARKET OUTLOOK NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and…

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted…